Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2022-05-23 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物：2021年年度股东大会法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2021 Annual General Meeting (AGM) of Shanghai Sailun Biotechnology Co., Ltd. It details the legality and validity of the AGM's convening, attendance, voting procedures, and resolutions. The document includes specific voting results and confirms compliance with relevant laws and company bylaws. It is not the AGM presentation materials themselves, nor is it an announcement of voting results only. It is a legal opinion related to the AGM proceedings. Given the content focuses on the AGM and its legal aspects, the most appropriate classification is AGM Information (AGM-R). The document length is over 6,000 characters, indicating it is a substantive report rather than a brief announcement or certification. Therefore, the classification is AGM-R with high confidence.
2022-05-23 Chinese
赛伦生物：2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2021 Annual General Meeting Resolution Announcement" from Shanghai SAILUN Biotech Co., Ltd. It details the date and method of the AGM, attendance, voting results on various proposals including the annual report, financial statements, profit distribution, auditor appointment, and director remuneration. It also includes legal witness statements confirming the legality and validity of the meeting and resolutions. The document is a formal announcement of the voting results and resolutions passed at the AGM, not the full annual report or financial statements themselves. The length is 3633 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-05-23 Chinese
赛伦生物：2021年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled "2021 年年度股东大会会议资料" which translates to "2021 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda items, reports, and proposals to be discussed and voted on at the 2021 AGM of Shanghai Sailun Biotechnology Co., Ltd. The content includes the meeting agenda, board and supervisory reports, financial statements, and proposals for shareholder approval. The document is clearly the presentation and materials shared during the AGM, not the full annual report or other filings. The length is substantial (15,000 characters), and it is not merely an announcement or a certification. Therefore, the document fits the category of AGM Information (AGM-R).
2022-05-16 Chinese
赛伦生物：关于疫情防控期间参加2021年年度股东大会相关注意事项的提示性公告
AGM Information Classification · 95% confidence The document is a notice from Shanghai Serum Bio-Tech Co., Ltd. regarding the arrangements and precautions for attending the 2021 Annual General Meeting (AGM) during the COVID-19 pandemic. It discusses the change in meeting format to remote participation and voting methods due to pandemic control measures. The document does not contain financial data, results, or detailed reports but rather logistical information about the AGM. It is an announcement related to the AGM, specifically about participation instructions and precautions, which fits the category of AGM Information (AGM-R). The document length is short and focused on the meeting arrangements, not the full AGM report or voting results.
2022-05-16 Chinese
赛伦生物：《信息披露暂缓与豁免业务管理制度》（2022年4月）
Governance Information Classification · 95% confidence The document is titled '信息披露暂缓与豁免业务管理制度' which translates to 'Information Disclosure Delay and Exemption Business Management System' for Shanghai Sairen Biotechnology Co., Ltd. It outlines internal policies and procedures related to the delay and exemption of information disclosure, referencing relevant securities laws and stock exchange rules. The content is regulatory and procedural in nature, focusing on compliance and internal controls rather than financial results, management changes, or shareholder communications. It does not contain financial statements, earnings data, or meeting materials. It is not an announcement or a report of financial performance or governance changes but a governance and compliance policy document. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 4105 characters, which is relatively short but contains substantive policy content, not just an announcement or certification, so it is not RPA or RNS.
2022-04-29 Chinese
赛伦生物：关于2022年度公司董事、监事薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the 2022 annual remuneration scheme for the company's directors and supervisors. It details the salary standards and approval process by the board and supervisory committee. It does not contain financial statements or performance data, nor is it a report or presentation. It specifically focuses on compensation information for top executives and directors, which aligns with the definition of Remuneration Information filings.
2022-04-29 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.